# US 10,118,055 B2 · Topical anti-pruritic compositions and methods of action of same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,118,055 B2 - Document ID: US10118055B2 - Status: Granted - Kind: B2 - Application number: 13/155,965 - Filed: 2011-06-08 - Published: 2011-09-29 - Granted: 2018-11-06 - Earliest claimed: 2005-07-27 - Assignees: Stiefel Laboratories, Inc. - Applicants: Kathleen L. Clark; Joanne M. Fraser - Inventors: Kathleen L. Clark; Joanne M. Fraser - Web page: https://patentgrep.com/patent/US10118055B2 ## CPC - A61K 8/31: Hydrocarbons - A61K 8/37: Esters of carboxylic acids - A61K 8/891: saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone - A61K 31/5375: 1,4-Oxazines, e.g. morpholine - A61P 17/00: Drugs for dermatological disorders - A61P 17/04: Antipruritics - A61Q 17/00: Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings - A61K 2800/75: Anti-irritant - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS ## Abstract Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective treatment of pruritus than do certain present pruritus-treating compositions. ## Claims ### Claim 1 A method for treating pruritus in a patient comprising administering to a patient suffering from pruritus a first topical composition that is a lotion consisting essentially of pramoxine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 to about 5% by weight, at least one occlusive skin conditioning agent in an amount from about 1 to about 10% by weight, an organosiloxane in an amount from about 0.5 to about 5% by weight, an emulsifier in an amount from about 0.5 to about 10% by weight, a gelling agent selected from the group consisting of gum arabic, gum tragacanth, locust beam gum, guar gum, xanthan gum, and carbomer, in an amount of about 0.1 to about 2% by weight, an emollient in an amount of about 0.01 to about 5% by weight, and an aqueous solvent in an amount from about 60 to about 90% by weight, wherein the administration of said first composition provides a more effective treatment of said pruritus in comparison to treatment of pruritus achieved by administration of a second topical composition comprising about 1% by weight hydrocortisone. ### Claim 2 (depends on 1) The method of claim 1, wherein said occlusive skin conditioning agent is petrolatum. ### Claim 3 (depends on 1) The method of claim 1, wherein said emollient has the following structural formula: wherein R1 can be a C7-C20 straight or branched alkane, C7-C20 straight or branched alkene, C7-C20 straight or branched alkyne, C7-C20 straight or branched alkanol, C7-C20 straight or branched alkenol, C7-C20 straight or branched alkynol, C7-C20 straight or branched ester, and C7-C20 straight or branched ether; and wherein R2 can be a C1-C8 straight or branched alkane, C1-C8 straight or branched alkanol, C1-C8 straight or branched ether, C3-C8cyclic hydrocarbon optionally substituted with at least one R3, C3-C8 aromatic hydrocarbon optionally substituted with at least one R3, and C3-C8 aryl optionally substituted with at least one R3; wherein R3 can be a C1-C8 straight or branched alkane, C1-C8 straight or branched alkene, C1-C8 straight or branched alkyne, C1-C8 straight or branched alkanol, C1-C8 straight or branched alkenol, C1-C8 straight or branched alkynol, C1-C8 straight or branched ester, and C1-C8 straight or branched ether. ### Claim 4 (depends on 1) The method of claim 1, wherein said topical anti-pruritic composition begins reducing symptoms of pruritus exhibited by said patient within about 15 minutes. ### Claim 5 (depends on 4) The method of claim 4, wherein said topical anti-pruritic composition begins reducing symptoms of pruritus exhibited by said patient within about 2 minutes. ### Claim 6 (depends on 1) The method of claim 1, wherein said topical anti-pruritic composition alleviates said pruritus within about 4 hours. ### Claim 7 (depends on 6) The method of claim 6, wherein said topical anti-pruritic composition alleviates said pruritus within about 1 hour. ### Claim 8 (depends on 3) The method of claim 3, wherein said emollient is isopropyl myristate.